Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Seagen Inc.
Alaunos Therapeutics
Elicio Therapeutics
Eli Lilly and Company
Incyte Corporation
Sirtex Medical
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Elevation Oncology
BioNTech SE
Servier
QED Therapeutics, a BridgeBio company
EpicentRx, Inc.
NextCure, Inc.
Basilea Pharmaceutica
Novo Nordisk A/S
EMD Serono
EMD Serono
PCI Biotech AS
Hoffmann-La Roche
Basilea Pharmaceutica
Celgene
Halozyme Therapeutics
Concordia Laboratories Inc.
Hoffmann-La Roche
Sanofi